Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vibeke Strand

Showing results (231-240 of 435) with videos related to

Pageof 44
Sort By:
The Journal of Rheumatology. Supplement|June 2, 2021
Report of the Skin Research Working Groups From the GRAPPA 2020 Annual MeetingLourdes M Perez-Chada, Alison Kohn, Alice B Gottlieb, et al.
RMD Open|January 16, 2021
Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combinationVibeke Strand, Philip J Mease, Ervant J Maksabedian Hernandez, et al.
Annals of the Rheumatic Diseases|February 1, 2017
Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort studyLars Erik Kristensen, Tanja S Jørgensen, Robin Christensen, et al.
Annals of the Rheumatic Diseases|January 15, 2013
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre studyDaniel J Wallace, Kenneth Kalunian, Michelle A Petri, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2020
Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled TrialRonald van Vollenhoven, Tsutomu Takeuchi, Aileen L Pangan, et al.
Arthritis and Rheumatism|February 7, 2003
LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled studyDonato Alarcón-Segovia, James A Tumlin, Richard A Furie, et al.
The Journal of Rheumatology|May 5, 2007
Systemic sclerosis - continuing progress in developing clinical measures of responseDaniel Furst, Dinesh Khanna, Marco Matucci-Cerinic, et al.
The Journal of Rheumatology|December 7, 2005
Measurement of joint space width and erosion sizeJohn T Sharp, Desiree van der Heijde, Jane Angwin, et al.
The Journal of Rheumatology|February 4, 2014
Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11Laura C Coates, Oliver FitzGerald, Philip J Mease, et al.
Rheumatology (Oxford, England)|June 27, 2018
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)Alice B Gottlieb, Vibeke Strand, Mitsumasa Kishimoto, et al.
Pageof 44

Showing results (231-240 of 435) with videos related to

Sort By:
Pageof 44
The Journal of Rheumatology. Supplement|June 2, 2021
Report of the Skin Research Working Groups From the GRAPPA 2020 Annual MeetingLourdes M Perez-Chada, Alison Kohn, Alice B Gottlieb, et al.
RMD Open|January 16, 2021
Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combinationVibeke Strand, Philip J Mease, Ervant J Maksabedian Hernandez, et al.
Annals of the Rheumatic Diseases|February 1, 2017
Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort studyLars Erik Kristensen, Tanja S Jørgensen, Robin Christensen, et al.
Annals of the Rheumatic Diseases|January 15, 2013
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre studyDaniel J Wallace, Kenneth Kalunian, Michelle A Petri, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2020
Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled TrialRonald van Vollenhoven, Tsutomu Takeuchi, Aileen L Pangan, et al.
Arthritis and Rheumatism|February 7, 2003
LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled studyDonato Alarcón-Segovia, James A Tumlin, Richard A Furie, et al.
The Journal of Rheumatology|May 5, 2007
Systemic sclerosis - continuing progress in developing clinical measures of responseDaniel Furst, Dinesh Khanna, Marco Matucci-Cerinic, et al.
The Journal of Rheumatology|December 7, 2005
Measurement of joint space width and erosion sizeJohn T Sharp, Desiree van der Heijde, Jane Angwin, et al.
The Journal of Rheumatology|February 4, 2014
Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11Laura C Coates, Oliver FitzGerald, Philip J Mease, et al.
Rheumatology (Oxford, England)|June 27, 2018
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)Alice B Gottlieb, Vibeke Strand, Mitsumasa Kishimoto, et al.
Pageof 44